Experimental drug INB03 tested to stop COVID-19 lung decline – trial halted early

NCT ID NCT04370236

Terminated Disease control Sponsor: Inmune Bio, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested a drug called INB03 in 79 high-risk COVID-19 patients to see if it could prevent their breathing from getting worse. Participants received two weekly injections of either INB03 or a placebo. The trial was terminated early, so we do not have clear results on whether the drug helped.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: INB03 (also called XPro1595 or Quellor)
What this could lead to: If it worked, this could point toward a treatment to prevent severe breathing problems in high-risk COVID-19 patients.
What could go wrong: The trial was terminated early with only 79 participants, so results are limited. It is unclear if INB03 is safe or effective for COVID-19.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COVID-19 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

COVID-19 cytokine release syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COVID-19

Contacts and locations

Locations

Baptist Clinical Research Institute

Memphis, Tennessee, 38120, United States
Baptist Memorial Hospital-DeSoto

Southard, Missouri, 38671, United States
Jewish Hospital

Louisville, Kentucky, 40202, United States
Memorial Hermann

Houston, Texas, 77030, United States
Memorial Hermann Southeast

Houston, Texas, 77089, United States
Mississippi Baptist

Kosciusko, Mississippi, 39090, United States
NEA Baptist

Jonesboro, Arkansas, 72401, United States
Richmond University Medical Center

Staten Island, New York, 10312, United States
St. Bernard's

Jonesboro, Arkansas, 72401, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.